Alerta

METHOD FOR PREPARING 4-(2-(DIFLUOROMETHOXY)PHENYL)-5-METHYLTHIAZOL-2-AMINE, WHICH EXHIBITS PREDICTED ACTIVITY AGAINST THE SARS-COV-2 VIRUS

Resumen de: UA164235U

Method for preparing 4-(2-(difluoromethoxy)phenyl)-5-methylthiazol-2-amine: , which exhibits predicted activity against the SARS-CoV-2 virus, according to which a mixture of equimolar amounts of 2-bromo-1-(2-(difluoromethoxy)phenyl)propan-1-one and thiourea is boiled for three hours in propan-2-ol, cooled, filtered and suspended in 50 ml of saturated NaHCO3 solution, stirred for 5 hours, filtered, washed with water, crystallized from propan-2-ol.

COMPOSITIONS AND METHODS FOR TREATMENT OF SUBJECTS SUFFERING FROM A SARS-COV-2 INFECTION

Resumen de: US20260256871A1

0000 The application is directed to methods for treatment or prevention of SARS-CoV-2 infection in a subject in need thereof, the composition comprising an organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically acceptable salt thereof, and methods of using the same.

BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE

Resumen de: US20260256905A1

0000 Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

MANUFACTURE OF CARBON SKIN POINTS FROM NATURAL SOURCES WITH BACTERICIDAL AND VIRICIDAL CAPACITY

Resumen de: MX2025002403A

The invention relates to a method for the green synthesis of carbon quantum dots with bactericidal and virucidal properties, formed from a mixture of: a plant extract as a carbon source with antioxidant and polyphenol-rich capacity (ratio of between 20-30%); a fruit extract as a source of oxygen rich in vitamin C and antioxidants (with a proportion of between 10-20%); and a plant extract as a source of nitrogen with a high antioxidant content (with a proportion of between 0.5-3%) in aqueous medium (50-60%) resulting in the production of a suspension CQDs having an average diameter of 5-15 nm, hemispherical morphology and with fluorescence emission capacity in blue. The invention includes the reaction process from the use of a pressure heating system and a series of filtrates, resulting in an aqueous suspension of CQDs doped with nitrogen and oxygen species in concentrations ranging from 0.1-30 mg/mL. As a result of the reaction, it is demonstrated that CQDs present the complete growth inhibition of S aureus and P aeruginosa, demonstrating their broad bactericidal capacity against common pathogens in hospital environments. Simultaneously, it is demonstrated that CQDs obtained by environmentally-friendly processes exhibit high virucidal capacity upon contact with viruses such as herpes simplex (HSV1) and SARS-CoV2 upon contact within Vero cells employed as huesped, leading to respiratory diseases. This results in the synthesis of antimicrobial carbon nanomaterials from natural

VALACYCLOVIR AND CELECOXIB IN COMBINATION WITH NIRMATRELVIR AND RITONAVIR FOR THE TREATMENT OF COVID-19

Resumen de: MX2026006843A

The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.

SARS-COV-2 Biomarkers for Predicting Severity of SARS-CoV-2 infectious disease

Resumen de: KR20260132653A

본 발명은 SARS-COV-2 바이러스 감염 질환의 중증도 예측용 바이오마커에 관한 것으로, SARS-COV-2 바이러스 감염 질환의 중증 환자 및 경증 환자에 대한 임상 데이터를 활용하여 cis-eQTM 분석을 통해 32종의 DNA 메틸화 마커 및 상기 DNA 메틸화 마커에 의해 차별적으로 발현되는 18종의 유전자 또는 단백질 마커를 제공한다.

ASSAYS FOR THE EVALUATION OF SEASONAL COVID-INFLUENZA COMBINATION VACCINES

Resumen de: US20260259196A1

Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) from a subject that has been administered a an immunogenic composition directed to a seasonal influenza virus and an immunogenic composition directed to a SARS-COV-2 virus contains antibodies that inhibit influenza virus hemagglutinin (HA) glycoprotein hemagglutination activity, antibodies that neutralize SARS-COV-2 virus, antibodies that bind SARS-COV-2 spike protein, and/or antibodies that neutralize seasonal influenza virus. The methods include assaying a biological sample, where the biological sample is from a subject that has been administered an immunogenic composition directed to a seasonal influenza virus and an immunogenic composition directed to a SARS-COV-2 virus, and is not significantly affected by interference of analyte detection between the methods.

COVID-19 AND RESPIRATORY DISEASE VIRUS INFECTION MODELS USING LUNG ORGANOIDS

Resumen de: US20260259197A1

The present invention relates to a COVID-19 infection model using alveolar organoids. Respiratory virus-infected alveolar organoids produced according to the present invention are expected to be usefully used in preclinical or clinical drug screening and the like for the development of therapeutic agents for SARS-CoV-2 infection.

ANTI-SARS-COV-2 SPIKE (S) IMMUNOASSAY AND METHODS OF USE THEREOF

Resumen de: US20260259220A1

0000 Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) contains IgA antibodies against SARS-CoV-2 S glycoproteins. The method includes contacting a biological sample with a SARS-CoV-2 S glycoprotein-coated surface, contacting the surface with a secondary antibody, and detecting the secondary antibody, where if a secondary antibody is detected, the sample contains IgA antibodies against the SARS-CoV-2 S glycoprotein. Assay substrates and kits for performing such methods are also disclosed.

COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19

Resumen de: CN122641466A

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

TREATMENT OF VIRAL INFECTION, DISEASE OR DISORDER USING A SELECTIVE S1R AGONIST

Resumen de: MX438089B

The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective SIR agonist. In another aspect, the viral disease is COVID-19, and the selective SIR agonist is pridopidine or pharmaceutically acceptable salt thereof.

SARS-CoV-2 Fc Recombinant adenovirus comprising SARS-CoV-2 derived receptor binding domain and antibody Fc region and uses thereof

Resumen de: WO2026182475A1

The present invention relates to a recombinant adenovirus comprising a SARS-CoV-2-derived receptor-binding domain and an antibody Fc region, and a use thereof, and provides: a polynucleotide comprising a SARS-CoV-2 spike-derived receptor-binding domain and an antibody Fc region; a recombinant adenovirus comprising the polynucleotide; and a vaccine composition for preventing SARS-COV-2 infection, comprising the recombinant adenovirus as an active ingredient.

USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION

Resumen de: EP4799624A2

Methods and compositions for treating RNA viral infections, including behavior symptoms of the RNA viral infections, are disclosed herein. Also disclosed are methods and compositions for reducing the progression of clinical complications associated with RNA viral infections. The methods, for example, can include administering pharmaceutical compositions comprising Pipendoxifene or analogues thereof (e.g., a compound of Formula (I), Formula (II), or Formula (III)) to a patient in need. One or more additional therapeutic agents can also be administered to the patient in the disclosed methods.

Nouveaux composés à base d’acides aminés modifiés comme inhibiteurs de la réplication du SARS-CoV-2, leurs formulations et applications

Resumen de: MA70856A1

Cette invention est relative à de nouveaux composés à base de lacide éthacrynique couplé avec des acides aminés modifiés comme lillustre la formule (I). Ces composés sont conçus pour le traitement du SARS-CoV-2, des pathologies liées à la COVID-19, ainsi que des maladies associées aux -coronavirus. Cette invention porte également sur leur application in vitro pour étudier l'inhibition de la réplication du SARS CoV2. De plus, cette invention inclut des compositions pharmaceutiques comprenant, comme principe actif, au moins un composé de la formule (I).

SARS-COV-2 ANTIBODIES AND METHODS OF USING THE SAME

Nº publicación: SI4514842T1 31/08/2026

Solicitante:

ASTRAZENECA UK LTD [GB]
AstraZeneca UK Limited

Resumen de: WO2023209177A1

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.